BioTech IP Review

What’s emerging

• Next-gen CAR-T and CAR-NK
• Allogeneic (“off-the-shelf”) cell therapies
• Engineered immune and stem cells

Why it’s promising

• Clinical validation already exists
• Engineering improvements drive each generation

IP significance

• Claims often hinge on cell type, modification method, and functional phenotype
• Manufacturing and persistence claims are increasingly valuable
• Enablement and written description are frequent pressure points